Charlotte Fieldhouse

This inventor holds 14 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 7 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Takeda Pharmaceutical Company Limited, Nxera Pharma UK Limited. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Charlotte Fieldhouse. Retrieved from https://idiyas.com/inventor/charlotte-fieldhouse

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 3)

% Patents Active = 78.6

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 8)

Average Co-Inventor Count = 6.1

ph-index = 4

Forward Citations = 45(Granted Patents)

Location History:

Cambridgeshire, GB (2017 - 2020)
Cambridge, GB (2015 - 2021)

Company Filing History:

12 out of 1,232

Takeda Pharmaceutical Company Limited

patents

2 out of 18

Nxera Pharma UK Limited

patents

Years Active: 2015-2026

Loading Chart...

Areas of Expertise:

H4 Antagonist Compounds

Pyrazole Derivatives

Pyridazinone Compounds

DAAO Inhibitors

Orexin Receptor Antagonists

Cyclopentanes

Cyclopentylbenzamide Derivatives

Therapeutic Applications

Cognitive Disorders

Psychotic Disorders

Enzyme Inhibition

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12774289 - H4 antagonist compounds (2026-10-27),

2. 12234227 - Pyrazole derivatives as H4 antagonist compounds (2025-02-25),

3. 12186313 - Pyridazinone compounds and their use as DAAO inhibitors (2025-01-07),

4. 11129828 - Pyridazinone compounds and their use as DAAO inhibitors (2021-09-28),

5. 10689373 - 1,2-substituted cyclopentanes as orexin receptor antagonists (2020-06-23),

6. 10463663 - Pyridazinone compounds and their use as DAAO inhibitors (2019-11-05),

7. 10011588 - 1,2-substituted cyclopentanes as orexin receptor antagonists (2018-07-03),

8. 9931340 - Pyridazinone compounds and their use as DAAO inhibitors (2018-04-03),

9. 9790220 - Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists (2017-10-17),

10. 9750748 - Pyridazinones as DAAO enzyme inhibitors (2017-09-05),

11. 9493432 - Cyclopentylbenzamide derivatives and their use for the treatment of psychotic and cognitive disorders (2016-11-15),

12. 9290456 - Pyridazinone compounds and their use as DAAO inhibitors (2016-03-22),

13. 9180122 - 5- or 6-substituted 3-hydroxy-2 (1 H)-pyridinones as D-amino acid oxidase (DAAO) inhibitors in therapy of diseases such as schizophrenia, cognitive disorder and pain (2015-11-10),

14. 9156829 - Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists (2015-10-13),

Title: Charlotte Fieldhouse: Innovator in Pharmaceutical Compounds

Introduction

Charlotte Fieldhouse is a prominent inventor based in Cambridge, GB. She has made significant contributions to the field of pharmaceuticals, holding a total of 13 patents. Her work primarily focuses on developing novel compounds that have therapeutic applications.

Latest Patents

Among her latest patents are "Pyrazole derivatives as H4 antagonist compounds" and "Novel compounds of formula (1): Pyridazinone compounds and their use as DAAO inhibitors." These inventions provide valuable compounds and processes for their preparation, as well as pharmaceutical compositions that can be utilized in therapy.

Career Highlights

Charlotte has worked with notable companies in the pharmaceutical industry, including Takeda Pharmaceutical Company Limited and Nxera Pharma UK Limited. Her experience in these organizations has allowed her to advance her research and contribute to innovative solutions in medicine.

Collaborations

Charlotte has collaborated with esteemed colleagues such as William John Farnaby and Catrina Kerr, further enhancing her work in the field.

Conclusion

Charlotte Fieldhouse is a distinguished inventor whose contributions to pharmaceutical compounds have the potential to impact therapeutic practices significantly. Her innovative spirit and dedication to research continue to drive advancements in the industry.

Profile summary based on public USPTO records.